Top

Published in:

01-01-2016 | Review

Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature

Authors: O. Bonnot, D. Cohen, D. Thuilleaux, A. Consoli, S. Cabal, M. Tauber

Published in: European Journal of Pediatrics | Issue 1/2016

Abstract

Prader-Willi syndrome (PWS) is a rare genetic syndrome. The phenotype includes moderate to intellectual disability, dysmorphia, obesity, and behavioral disturbances (e.g., hetero and self-injurious behaviors, hyperphagia, psychosis). Psychotropic medications are widely prescribed in PWS for symptomatic control. We conducted a systematic review of published literature to examine psychotropic medications used in PWS. MEDLINE was searched to identify articles published between January 1967 and December 2014 using key words related to pharmacological treatments and PWS. Articles with original data were included based on a standardized four-step selection process. The identification of studies led to 241 records. All selected articles were evaluated for case descriptions (PWS and behavioral signs) and treatment (type, titration, efficiency, and side effects). Overall, 102 patients were included in these studies. Treatment involved risperidone (three reports, n = 11 patients), fluoxetine (five/n = 6), naltrexone (two/n = 2), topiramate (two/n = 16), fluvoxamine (one/n = 1), mazindol (one/n = 2), N-acetyl cysteine (one/n = 35), rimonabant (one/n = 15), and fenfluramine (one/n = 15).

Conclusion: We identified promising treatment effects with topiramate for self-injury and impulsive/aggressive behaviors, risperidone for psychotic symptoms associated with uniparental disomy (UPD), and N-acetyl cysteine for skin picking. The pharmacological approach of behavioral impairment in PWS has been poorly investigated to date. Further randomized controlled studies are warranted.

What is Known:

• Behavioral disturbances in Prader-Willi syndrome including aggressive reactions, skin picking, and hyperphagia might be very difficult to manage.

• Antipsychotic drugs are widely prescribed, but weight gain and increased appetite are their major side effects.

What is New:

• Topiramate might be efficient for self-injury and impulsive/aggressive behaviors, N-acetyl cysteine is apromising treatment for skin picking and Antidepressants are indicated for OCD symptoms.

• Risperidone is indicated in case of psychotic symptoms mainly associated with uniparental disomy.

Adams S, Penton-Voak IS, Harmer CJ, Holmes EA, Munafo MR (2013) Effects of emotion recognition training on mood among individuals with high levels of depressive symptoms: study protocol for a randomised controlled trial. Trials 14:161. doi:10.1186/1745-6215-14-161 PubMedCentralCrossRefPubMed

Amrouche-Mekkioui I, Djerdjouri B (2012) N-acetylcysteine improves redox status, mitochondrial dysfunction, mucin-depleted crypts and epithelial hyperplasia in dextran sulfate sodium-induced oxidative colitis in mice. Eur J Pharmacol 691:209–217. doi:10.1016/j.ejphar.2012.06.014 CrossRefPubMed

Araki S, Ohji T, Shiota N, Dobashi K, Shimono M, Shirahata A (2010) Successful risperidone treatment for behavioral disturbances in Prader-Willi syndrome. Pediatrics international : official journal of the Japan Pediatric Society 52:e1–e3. doi:10.1111/j.1442-200X.2009.02996.x CrossRef

Arbaizar B, Gomez-Acebo I, Llorca J (2008) Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review. Gen Hosp Psychiatry 30:471–475CrossRefPubMed

Banga A, Connor DF (2012) Effectiveness of naltrexone for treating pathologic skin picking behavior in an adolescent with Prader-Willi syndrome. J Child Adolesc Psychopharmacol 22:396–398. doi:10.1089/cap.2012.0028 CrossRefPubMed

Beardsmore A, Dorman T, Cooper SA, Webb T (1998) Affective psychosis and Prader-Willi syndrome. J Intellect Disabil Res 42(Pt 6):463–471CrossRefPubMed

Benarroch F, Hirsch HJ, Genstil L, Landau YE, Gross-Tsur V (2007) Prader-Willi syndrome: medical prevention and behavioral challenges. Child Adolesc Psychiatr Clin N Am 16:695–708. doi:10.1016/j.chc.2007.03.007 CrossRefPubMed

Benjamin E, Buot-Smith T (1993) Naltrexone and fluoxetine in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 32:870–873. doi:10.1097/00004583-199307000-00025 CrossRefPubMed

Bertella L, Girelli L, Grugni G, Marchi S, Molinari E, Semenza C (2005) Mathematical skills in Prader-Willi Syndrome. J Intellect Disabil Res 49:159–169CrossRefPubMed

10.

Biederman J, Faraone SV (2005) Attention-deficit hyperactivity disorder. Lancet 366:237–248. doi:10.1016/S0140-6736(05)66915-2 CrossRefPubMed

11.

Boer H, Holland A, Whittington J, Butler J, Webb T, Clarke D (2002) Psychotic illness in people with Prader Willi syndrome due to chromosome 15 maternal uniparental disomy. Lancet 359:135–136CrossRefPubMed

12.

Buiting K (2010) Prader-Willi syndrome and Angelman syndrome. Am J Med Genet C: Semin Med Genet 154C:365–376. doi:10.1002/ajmg.c.30273 CrossRef

13.

Butler MG, Smith BK, Lee J, Gibson C, Schmoll C, Moore WV, Donnelly JE (2013) Effects of growth hormone treatment in adults with Prader-Willi syndrome. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 23:81–87. doi:10.1016/j.ghir.2013.01.001 CrossRef

14.

Clarke D (1998) Prader-Willi syndrome and psychotic symptoms: 2. A preliminary study of prevalence using the Psychopathology Assessment Schedule for Adults with Developmental Disability checklist. J Intellect Disabil Res 42(Pt 6):451–454CrossRefPubMed

15.

Deb S, Unwin G, Deb T (2014) Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour. J Intellect Disabil Res. doi:10.1111/jir.12119

16.

Dech B, Budow L (1991) The use of fluoxetine in an adolescent with Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 30:298–302. doi:10.1097/00004583-199103000-00020 CrossRefPubMed

17.

Dolengevich Segal H, Rodriguez Salgado B, Conejo Garcia A, San Sebastian Cabases J (2006) Efficacy of topiramate in children and adolescent with problems in impulse control: preliminary results. Actas Esp Psiquiatr 34:280–282PubMed

18.

Duggan L, Brylewski J (1999) Effectiveness of antipsychotic medication in people with intellectual disability and schizophrenia: a systematic review. J Intellect Disabil Res 43(Pt 2):94–104CrossRefPubMed

19.

Durst R, Rubin-Jabotinsky K, Raskin S, Katz G, Zislin J (2000) Risperidone in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 39:545–546. doi:10.1097/00004583-200005000-00004 CrossRefPubMed

20.

Durst R, Rubin-Jabotinsky K, Raskin S, Katz G, Zislin J (2000) Risperidone in treating behavioural disturbances of Prader-Willi syndrome. Acta Psychiatr Scand 102:461–465CrossRefPubMed

21.

Dykens EM, Roof E (2008) Behavior in Prader-Willi syndrome: relationship to genetic subtypes and age. J Child Psychol Psychiatry 49:1001–1008CrossRefPubMed

22.

Fieldstone A, Zipf WB, Sarter MF, Berntson GG (1998) Food intake in Prader-Willi syndrome and controls with obesity after administration of a benzodiazepine receptor agonist. Obes Res 6:29–33CrossRefPubMed

23.

Francey SM, Nelson B, Thompson A, Parker AG, Kerr M, Macneil C, Fraser R, Hughes F, Crisp K, Harrigan S, Wood SJ, Berk M, McGorry PD (2010) Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophr Res 119:1–10CrossRefPubMed

24.

Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M, speakers contributors at the Second Expert Meeting of the Comprehensive Care of Patients with PWS (2008) Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab 93:4183–4197. doi:10.1210/jc.2008-0649 CrossRef

25.

Hassler F, Reis O (2010) Pharmacotherapy of disruptive behavior in mentally retarded subjects: a review of the current literature. Dev Disabil Res Rev 16:265–272. doi:10.1002/ddrr.119 CrossRefPubMed

26.

Herguner S, Mukaddes NM (2007) Psychosis associated with fluoxetine in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 46:944–945. doi:10.1097/chi.0b013e318068fbed CrossRefPubMed

27.

Itoh M, Koeda T, Ohno K, Takeshita K (1995) Effects of mazindol in two patients with Prader-Willi syndrome. Pediatr Neurol 13:349–351CrossRefPubMed

28.

Jauregi J, Arias C, Vegas O, Alen F, Martinez S, Copet P, Thuilleaux D (2007) A neuropsychological assessment of frontal cognitive functions in Prader-Willi syndrome. J Intellect Disabil Res 51:350–365CrossRefPubMed

29.

Kennedy GM, Lhatoo SD (2008) CNS adverse events associated with antiepileptic drugs. CNS Drugs 22:739–760CrossRefPubMed

30.

Khan A, Faught E, Gilliam F, Kuzniecky R (1999) Acute psychotic symptoms induced by topiramate. Seizure 8:235–237CrossRefPubMed

31.

Kohn Y, Weizman A, Apter A (2001) Aggravation of food-related behavior in an adolescent with Prader-Willi syndrome treated with fluvoxamine and fluoxetine. Int J Eat Disord 30:113–117CrossRefPubMed

32.

Kyriakides M, Silverstone T, Jeffcoate W, Laurance B (1980) Effect of naloxone on hyperphagia in Prader-Willi syndrome. Lancet 1:876–877CrossRefPubMed

33.

Lee YJ, Marcu S, Berall G, Shapiro CM (2011) Tryptophan for the treatment of excessive daytime sleepiness in Prader-Willi syndrome. Indian Pediatr 48:319–321CrossRefPubMed

34.

Lin G, Lawrence R (2006) Pediatric case report of topiramate toxicity. Clin Toxicol (Phila) 44:67–69CrossRef

35.

Matthews SC, Miller BP (2001) Auditory hallucinations associated with topiramate. J Clin Psychiatry 62:653CrossRefPubMed

36.

Miller JL, Angulo M (2014) An open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndrome. Am J Med Genet A 164:421–424. doi:10.1002/ajmg.a.36306 CrossRef

37.

Morgan JR, Storch EA, Woods DW, Bodzin D, Lewin AB, Murphy TK (2010) A preliminary analysis of the phenomenology of skin-picking in Prader-Willi syndrome. Child Psychiatry Hum Dev 41:448–463. doi:10.1007/s10578-010-0180-7 CrossRefPubMed

38.

Motaghedi R, Lipman EG, Hogg JE, Christos PJ, Vogiatzi MG, Angulo MA (2011) Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome. Eur J Med Genet 54:14–18. doi:10.1016/j.ejmg.2010.09.015 PubMedCentralCrossRefPubMed

39.

Mula M, Trimble MR, Lhatoo SD, Sander JW (2003) Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 44:659–663CrossRefPubMed

40.

Orphanet (2013) Prevalence of rare diseases. http://www.orpha.net/orphacom/cahiers/docs/FR/Prevalence_des_maladies_rares_par_prevalence_decroissante_ou_cas.pdf. Accessed January 2014

41.

Rana F, Gormez A, Varghese S (2013) Pharmacological interventions for self-injurious behaviour in adults with intellectual disabilities. The Cochrane database of systematic reviews 4:CD009084. doi:10.1002/14651858.CD009084.pub2 PubMed

42.

Reas DL, Grilo CM (2008) Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity (Silver Spring) 16:2024–2038CrossRef

43.

Reis AD, Castro LA, Faria R, Laranjeira R (2008) Craving decrease with topiramate in outpatient treatment for cocaine dependence: an open label trial. Rev Bras Psiquiatr 30:132–135CrossRefPubMed

44.

Schepis C, Failla P, Siragusa M, Palazzo R, Romano C (1998) Failure of fluoxetine to modify the skin-picking behaviour of Prader-Willi syndrome. Australas J Dermatol 39:57–58CrossRefPubMed

45.

Selikowitz M, Sunman J, Pendergast A, Wright S (1990) Fenfluramine in Prader-Willi syndrome: a double blind, placebo controlled trial. Arch Dis Child 65:112–114PubMedCentralCrossRefPubMed

46.

Semenza C, Pignatti R, Bertella L, Ceriani F, Mori I, Molinari E, Giardino D, Malvestiti F, Grugni G (2008) Genetics and mathematics: evidence from Prader-Willi syndrome. Neuropsychologia 46:206–212CrossRefPubMed

47.

Shapira NA, Lessig MC, Lewis MH, Goodman WK, Driscoll DJ (2004) Effects of topiramate in adults with Prader-Willi syndrome. American journal of mental retardation : AJMR 109:301–309. doi:10.1352/0895-8017(2004)109<301:EOTIAW>2.0.CO;2 CrossRefPubMed

48.

Shapira NA, Lessig MC, Murphy TK, Driscoll DJ, Goodman WK (2002) Topiramate attenuates self-injurious behaviour in Prader-Willi Syndrome. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum 5:141–145. doi:10.1017/S1461145702002833

49.

Sinnema M, Boer H, Collin P, Maaskant MA, van Roozendaal KE, Schrander-Stumpel CT, Curfs LM (2011) Psychiatric illness in a cohort of adults with Prader-Willi syndrome. Res Dev Disabil 32:1729–1735. doi:10.1016/j.ridd.2011.02.027 CrossRefPubMed

50.

Skokauskas N, Sweeny E, Meehan J, Gallagher L (2012) Mental health problems in children with prader-willi syndrome. Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l’Academie canadienne de psychiatrie de l’enfant et de l’adolescent 21:194–203PubMed

51.

Smathers SA, Wilson JG, Nigro MA (2003) Topiramate effectiveness in Prader-Willi syndrome. Pediatr Neurol 28:130–133CrossRefPubMed

52.

Soni S, Whittington J, Holland AJ, Webb T, Maina E, Boer H, Clarke D (2007) The course and outcome of psychiatric illness in people with Prader-Willi syndrome: implications for management and treatment. J Intellect Disabil Res 51:32–42. doi:10.1111/j.1365-2788.2006.00895.x CrossRefPubMed

53.

Soni S, Whittington J, Holland AJ, Webb T, Maina EN, Boer H, Clarke D (2008) The phenomenology and diagnosis of psychiatric illness in people with Prader-Willi syndrome. Psychol Med 38:1505–1514PubMed

54.

Stella F, Caetano D, Cendes F, Guerreiro CA (2002) Acute psychotic disorders induced by topiramate: report of two cases. Arq Neuropsiquiatr 60:285–287CrossRefPubMed

55.

Unwin GL, Deb S (2011) Efficacy of atypical antipsychotic medication in the management of behaviour problems in children with intellectual disabilities and borderline intelligence: a systematic review. Res Dev Disabil 32:2121–2133. doi:10.1016/j.ridd.2011.07.031 CrossRefPubMed

56.

Van Borsel J, Defloor T, Curfs LM (2007) Expressive language in persons with Prader-Willi syndrome. Genet Couns 18:17–28PubMed

57.

Vogels A, Matthijs G, Legius E, Devriendt K, Fryns JP (2003) Chromosome 15 maternal uniparental disomy and psychosis in Prader-Willi syndrome. J Med Genet 40:72–73PubMedCentralCrossRefPubMed

58.

Whitman BY, Accardo P (1987) Emotional symptoms in Prader-Willi syndrome adolescents. Am J Med Genet 28:897–905CrossRefPubMed

59.

Whittington J, Holland A, Webb T, Butler J, Clarke D, Boer H (2004) Academic underachievement by people with Prader-Willi syndrome. J Intellect Disabil Res 48:188–200CrossRefPubMed

60.

Wu K, Hanna GL, Easter P, Kennedy JL, Rosenberg DR, Arnold PD (2013) Glutamate system genes and brain volume alterations in pediatric obsessive-compulsive disorder: a preliminary study. Psychiatry Res 211:214–220. doi:10.1016/j.pscychresns.2012.07.003 PubMedCentralCrossRefPubMed

Title: Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature
Authors: O. Bonnot
D. Cohen
D. Thuilleaux
A. Consoli
S. Cabal
M. Tauber
Publication date: 01-01-2016
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Pediatrics / Issue 1/2016
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-015-2670-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

Late detection of cleft palate

Epidemiology of multiple sclerosis in the pediatric population of Sardinia, Italy

Increased left atrial size in obese children and its association with insulin resistance: a pilot study

Volume-targeted versus pressure-limited ventilation in infants born at or near term

Genealogy of breastfeeding

Sporadic paraganglioma caused by de novo SDHB mutations in a 6-year-old girl